In-vivo administration of interleukin 1 both enhances and suppresses contact sensitivity in the mouse.
The in-vivo effects of systemic administration of recombinant human interleukin 1 beta (rIL-1 beta) were studied in the mouse contact-sensitivity model. rIL-1 beta in a single dose of 20 micrograms injected intraperitoneally 72-48 h before or 2-24 h after sensitization suppressed contact sensitivity. Given before challenge rIL-1 beta modulated the response in a biphasic way with an enhancement at 48 h and a suppression at 2 h before challenge. Only microgram doses of rIL-1 beta could enhance the contact sensitivity at 48 h, while microgram doses of rIL-1 beta at 2 h before challenge suppressed and nanogram doses enhanced the response. Treatment with indomethacin could only abrogate the effects of nanogram doses of rIL-1 beta. Measurements of the thickness of unchallenged control ears revealed that rIL-1 beta by itself could cause a small but significant increase in thickness depending on the dose and the time of administration.
Bäck
O
O
Department of Dermatology, University Hospital, Umeå, Sweden.
Linna
J
J
D000818:Animals; D003877:Dermatitis, Contact / Q000276:immunology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004431:Ear, External / Q000187:drug effects; D005260:Female; D007213:Indomethacin / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D007375:Interleukin-1 / Q000008:administration & dosage*; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000008:administration & dosage; D012867:Skin / Q000187:drug effects / Q000276:immunology*; D013997:Time Factors
D007375:Interleukin-1; D011994:Recombinant Proteins; D007213:Indomethacin